Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.68 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054852 | 0.92 | FDPS (0.67) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL8825784 | 0.92 | FDPS (0.77) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL4104675 | 0.87 | FDPS (0.73) | FDPSSMPD1PDE3ALMNAADRB3 | |
| Water SCHEMBL5162288 | 0.84 | FDPS (0.70) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL1285640 | 0.83 | FDPS (0.65) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL5162874 | 0.81 | FDPS (0.64) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL3414399 | 0.81 | FDPS (1.00) | FDPSSMPD1GGPS1 | |
| SCHEMBL1286213 | 0.81 | FDPS (0.67) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL11327768 | 0.81 | FDPS (0.70) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL1285910 | 0.80 | FDPS (0.64) | FDPSSMPD1PDE3ALMNAADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | FDPS 1920/4885SMPD1 118/4885PDE3A 685/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | FDPS 4116/4885SMPD1 536/4885PDE3A 1674/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FDPS 4229/4885SMPD1 610/4885PDE3A 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.